BioMarin's Vimizim and Lilly's Trulicity square off in drug-name tourney championship

Back in March, we at FiercePharmaMarketing put together a little competition of sorts--in the classic March bracket tournament fashion--for newly approved drugs to duke it out in the "best-named" arena.

The contest featured close calls, upsets, and Cinderella runs aplenty, and when all was said and done, it was BioMarin's ($BMRN) Vimizim and Eli Lilly's ($LLY) Trulicity staring each other down in the final match.

Who would come away victorious? Would it be Vimizim, which one reader said "sounds like a car revving its engine to win this race"? Or Trulicity, which another said "sounds like a vacation destination that would be hyped by an unethical travel agent"?

Spoiler alert: Vimizim took the title, crushing its rival by a voting tally of 6,783-4,881.

You can read more about the tournament here and more about the Vimizim-Trulicity matchup here. About the eventual champion? Check it out here.

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.